Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) EPS (Weighted Average and Diluted) (2017 - 2026)

Champions Oncology (CSBR) has 13 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.02 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 60.0% year-over-year to $0.02; the TTM value through Oct 2025 reached $0.17, up 383.33%, while the annual FY2025 figure was $0.33, 161.11% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.02 in Q4 2025 per CSBR's latest filing, up from -$0.03 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.31 in Q1 2025 and bottomed at -$0.19 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.03, with a median of -$0.02 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 29026.12% in 2021, then crashed 12576.4% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.02 in 2021, then plummeted by 105.92% to -$0.0 in 2022, then tumbled by 12576.4% to -$0.15 in 2023, then skyrocketed by 133.33% to $0.05 in 2024, then crashed by 60.0% to $0.02 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.02 in Q4 2025, -$0.03 in Q3 2025, and -$0.13 in Q2 2025.